Showing 7701-7710 of 8159 results for "".
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- mysoscience Launches Novel Pain Treatmenthttps://practicaldermatology.com/news/20140516-mysoscience_launches_novel_pain_treatment/2459238/myoscience, inc., has launched ioveradegrees, a new option to immediately block pain using the body's natural response to cold without the use of drugs or surgery. The ioveradegrees health treatment utilizes myoscience's platform technology—the Focused Cold Therapy(TM) delivery system—to precisely t
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Bayer Acquires Merck's Consumer Care Business in a $14.2 Billion Cash Transactionhttps://practicaldermatology.com/news/20140508-bayer_acquires_mercks_consumer_care_business_in_a_142_billion_cash_transaction/2459244/Bayer is set to purchase the consumer care unit of Merck and Co., Inc. in a transaction valued at $14.2 billion, acquiring popular products in the cold, allergy, sinus & flu, dermatology (including sun care), foot health and gastrointestinal categories. Bayer's acquisition of Merck's OTC products
- The XV World Congress on Cancers of the Skin to be Held in Edinburghhttps://practicaldermatology.com/news/20140501-the_xv_world_congress_on_cancers_of_the_skin_to_be_held_in_edinburgh/2459248/The XV World Congress on Cancers of the Skin, co-sponsored by The Skin Cancer Foundation and the British Association of Dermatologists, will be held at the Edinburgh International Conference Centre in Edinburgh, Scotland, September 3-6, 2014. The World Congress provides an opportunity for physic
- Researchers Examine UV Nail Salon Lamps and Risk of Skin Cancerhttps://practicaldermatology.com/news/20140501-researchers_examine_uv_nail_salon_lamps_and_risk_of_skin_cancer/2459249/A recent research letter in JAMA Dermatology stated that although using higher-wattage ultra violet (UV) lamps at nail salons to dry and c
- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions.&nbs
- Survey Finds Rosacea Sufferers' More Likely to be Judged Negatively Upon First Impressionhttps://practicaldermatology.com/news/20140428-survey_finds__rosacea_sufferers_more_likely_to_be_judged_negatively_upon_first_impression/2459251/A new survey by the National Rosacea Society finds that rosacea sufferers' are often judged negatively upon first impression. Shy, nervous, and stressed are the three words respondents used to describe their view of an individual with redness on their face, without knowing anything about them.
- Outrun the Sun Marks 10 Years of Sun Safety Education and Melanoma Researchhttps://practicaldermatology.com/news/20140428-outrun_the_sun_marks_10_years_of_sun_safety_education_and_melanoma_research/2459253/Outrun the Sun, Inc. (OTS), a nonprofit organization that has raised more than $1 million in support of skin cancer education and melanoma research, celebrates their 10 year anniversary. OTS was formed by Anita Day, Jonna MacDougall, Marci Reddick and Jennifer Patton Sarno because they h